The test provides accurate and stratified risk assessment insights to help guide clinical decisions for prostate cancer patients. Credit: National Cancer Institute / Unsplash.

Diagnostic solutions developer LynxDx has launched a new, non-invasive urine prostate cancer screening test, MyProstateScore 2.0 (MPS2).

A data-driven test, MPS2 has been designed to provide accurate and stratified risk assessment insights to guide clinical decisions for elevated prostate-specific antigen (PSA) patients or people with abnormal digital rectal exam (DRE) findings.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It offers an individualised risk score that helps physicians and patients make decisions on whether to proceed with a prostate biopsy.

The convenient, informative test allows doctors to improve prostate cancer screening accuracy compared to using PSA alone.

The foundation of MPS2 is a new gene fusion, T2:ERG, which is present in most prostate cancer patients. It is said to be the most specific prostate cancer biomarker.

MPS2 combines the specificity of the T2:ERG gene fusion with 17 other genetic biomarkers that help with clinically significant prostate cancer diagnoses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It uses the 18 biomarkers to evaluate prostate cancer risk with a 99% negative predictive value (NPV) for patients with a prior negative biopsy and 95% NPV for biopsy-naïve patients.

LynxDx chief medical and commercial officer Spencer Heaton said: “MyProstateScore 2.0 is a highly accurate, non-invasive post-DRE urine test capable of assessing with precise accuracy a patient’s individualised risk of having clinically significant prostate cancer.

“This insight enables providers and patients to determine the most appropriate next steps in the patient’s care, as the path is unique for each person.

“By using MPS2, clinicians can more confidently inform their patients whether or not a clinically significant cancer is present, or if their elevated PSA result was due to other factors.”